J.P. Morgan says Perrigo Company plc’s PRGO first-quarter 2025 earnings will be dominated by commentary on the potential impact of tariffs. The analyst says, “Tariffs could potentially have a significant impact on PRGO’s near-term earnings.”Analysts forecast adjusted earnings of 55 cents per share, with sales of $1.09 billion.Analyst Chris Schott says tariffs could lead the OTC drugs company to a low to mid-single-digit impact on global COGS on an annualized basis, and that the company expects to offset thi ...